G1 Believes Boehringer Is Better Bet To Sell Trilaciclib
Drops Plans To Market Alone In US
G1 Therapeutics had been talking about marketing its recently filed myelosuppression therapy for small cell lung cancer on its own. However a deal with Boehringer represents an alternative "capital efficient launch structure."
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them.